GlaxoSmithKline to meet the needs of ADHD sufferers

GlaxoSmithKline (GSK) looks forward to meeting the needs of adult’s with Attention Deficit Hyperactivity Disorder (ADHD).

The company has entered a three-year agreement with Shire to co-promote Vyvanse which is intended to treat patients with this condition.

Marketing of the treatment will begin in May by the GSK sales team and it will add an important product to the firm’s neurosciences portfolio.

Deirdre Connelly, president of the pharmaceutical division of the business, remarked the company is in a good position to promote the drug and to provide information to physicians.

“GSK has been active in discovering and developing medicines to treat psychiatric disorders for decades – and neuroscience is one of the company’s key therapeutic categories,” she commented.

Vyvanse has already been approved by the Food and Drug Administration to treat children aged six to 12 who suffer from ADHD.

Last week, GSK released its corporate responsibility report, which highlighted its plans to make medicines available to people across the globe.

Flexible pricing was one key area the firm said it would focus on.